Trial published looking at Extended VTE treatment with Rivaroxaban

A RCT was published in the New England Journal of Medicine in March 2017 looking at equipoise patients who had completed six to twelve months of treatment for VTE. A total of 3396 patients were randomised to receive either aspirin 100mg daily or Rivaroxaban (10mg or 20mg) once daily. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding.

The results seen were the primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups.

The conclusions Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates.

The abstract is available at http://www.nejm.org/doi/full/10.1056/NEJMoa1700518

 

Betrixaban approved in the USA for Medical Prophylaxis for high risk patients

In a recent article in the New England Journal of Medicine a trial involving Betrixaban, a direct factor Xa inhibitor, in extended prophylaxis for acutely unwell medical patients comparing this with Enoxaparin injections. The full article can be accessed here http://www.nejm.org/doi/full/10.1056/NEJMoa1601747#t=abstract

 

This medication however is currently only licensed in the United States where it has received FDA approval and can not currently be used in Europe

CLOT Conference 2017

The conference on Friday the 20th October 2017 at the Crown Plaza is now open for booking. This year all bookings are to be made via the website and paid via PayPal. This is our 21st year so looking forward to another great conference

CLOT Conference 2017 First Notice

The CLOT conference for 2017 has been moved and will now be held at the Crowne Plaza hotel on the 20th October 2017 with the usual overnight stay from the 19th October. This followed feedback from last year's conference with nobody feeling a different venue would impact upon whether members would attend. We have held prices from last year but are moving toward pay pal or online payment only. The programme is still being finalised and will be updated on the website when this is confirmed.

CLOT Conference and Website Survey

We have recently sent out a survey to all members looking at our annual conference and website to look at what we can improve and what members want to see. Many thanks to those who have responded but would be great to get some more feedback so please complete the survey link below.

Can we also take this opportunity to wish all CLOT members a Merry Christmas and a Happy New Year                 

 

https://www.surveymonkey.co.uk/r/3BD93MP

 The CLOT Committee